The study was performed after the first 150 mg of rifabutin was orally administered on 2 successive days. The patient received the drug after one haemodialysis session and the study was started immediately. Rifabutin haemodialysis clearance was determined during the following dialysis session, without re-administration of the drug. Blood samples were collected just before oral administration and at 0.5, 1, 2, 3, 4, 6, 8, 24 and 48 h afterwards, on the off-dialysis day. On the dialysis day, one paired arterial and venous blood sample was drawn 2 h after the start of haemodialysis. At the same time, dialysate samples were collected from the influx and efflux lines of the dialysing unit. Haemodialysis was performed for 4 h using a F60 polysulphone dialyser every 2 days with a double-needle access to an arteriovenous fistula, at a constant dialysate flow rate of 500 mlumin and blood flow rate of between 250 and 300 mlumin. Plasma rifabutin levels were determined by high pressure liquid chromatography.
The pharmacokinetic parameters of rifabutin are summarized in Table 1 . The values of extraction ratio and haemodialysis clearance of rifabutin were 22% and 66 mlumin, respectively. The value of F HD , which represents the ratio of haemodialysis clearance to total body clearance, was 21%. F HD was therefore below the 25% cut-off value, over which haemodialysis clearance should be considered clinically significant w4x.
In the patient, T max (time to peak concentration) and T 1u2 (terminal elimination half-life) were similar to subjects with normal renal function (4 vs 2 h, and 36.5 vs 32-67 h, respectively). C max (maximum plasma concentration) in the patient was less than half the upper level of the normal range for patients receiving twice the dose of rifabutin. Thus, the pharmacokinetics of rifabutin in our patient seemed not to be altered compared to reference values in healthy volunteers receiving a 300 mg daily dose. Furthermore, rifabutin was not significantly removed by haemodialysis according to the value of F HD .
According to these results, we suggest that rifabutin can be administered at a normal 300 mguday dosage schedule in patients with ESRD. However, it will be necessary to study rifabutin pharmacokinetics in larger number of haemodialysis patients receiving 300 mguday to confirm our conclusion. Furthermore, rifabutin may be administered regardless of the haemodialysis schedule since we have shown that rifabutin is not significantly removed by dialysis. C max , maximum plasma concentration; C min , minimum plasma concentration; T max , time to peak concentration; T 1u2 , terminal elimination half-life; AUC (0-48), area under the concentration-time curve from 0 to 48 hours after administration; VduF, apparent volume of distribution; CLuF, apparent total body clearance.
